Charles River Laboratories International Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $2.53B | $241.2M |
| FY2022 | — | $2.98B | $233.9M |
| FY2023 | — | $3.60B | $276.8M |
| FY2024 | — | $3.46B | $194.6M |
| FY2025 | — | $3.16B | $213.8M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $2.53B | $241.2M |
| FY2022 | — | $2.98B | $233.9M |
| FY2023 | — | $3.60B | $276.8M |
| FY2024 | — | $3.46B | $194.6M |
| FY2025 | — | $3.16B | $213.8M |